Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA: 600329)

China flag China · Delayed Price · Currency is CNY
34.70
+0.17 (0.49%)
Nov 12, 2024, 3:00 PM CST
14.18%
Market Cap 23.00B
Revenue (ttm) 8.04B
Net Income (ttm) 932.37M
Shares Out 770.16M
EPS (ttm) 1.21
PE Ratio 28.44
Forward PE 23.32
Dividend 1.28 (3.69%)
Ex-Dividend Date Jul 12, 2024
Volume 10,218,583
Open 34.55
Previous Close 34.53
Day's Range 34.35 - 35.77
52-Week Range 23.40 - 39.05
Beta 0.76
Analysts n/a
Price Target n/a
Earnings Date Oct 31, 2024

About Tianjin Pharmaceutical Da Ren Tang Group Corporation

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongji... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600329
Full Company Profile

Financial Performance

In 2023, Tianjin Pharmaceutical Da Ren Tang Group Corporation's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.

Financial Statements

News

There is no news available yet.